Three psychedelics stocks surge after Trump executive order. Oppenheimer sees more upside ahead

Trump’s executive order could materially improve the regulatory path for psychedelic drugs by prioritizing FDA vouchers and expanding investigational patient access through the DEA, a structural positive for the sector. Oppenheimer says the move should accelerate approvals, reduce development risk, and support larger clinical trials, with federal funding also helping ease research barriers. Compass Pathways shares jumped more than 35%, AtaiBeckley gained over 25%, and Definium rose more than 1% on the news.

Analysis

This is less about a one-day sympathy rally and more about the market re-rating the probability distribution of approval and reimbursement. The key second-order effect is that regulatory bottlenecks shift from being a binary clinical risk to a capacity and execution problem: the winners are the platforms with the strongest patent estates, cleaner development pathways, and enough balance-sheet runway to scale trials quickly once government tailwinds lower friction.

ATAI and CMPS should benefit most because a faster review cycle and broader pre-approval access disproportionately help companies with advanced lead assets and the most visible clinical datasets. The hidden loser is any smaller private/early-stage program that was relying on a slow, underfunded process; if capital starts concentrating into the best-known names, the sector’s financing bar rises and weaker assets may get stranded or forced into dilutive raises at worse terms.

The market may be underestimating how quickly sentiment can mean-revert if the policy language proves more symbolic than operational. The real test is whether priority vouchers and investigational access translate into actual trial starts, VA participation, and payer dialogue over the next 3-9 months; if implementation lags, the move can fade as a classic policy headline trade. Another risk is that any adverse safety signal in a high-visibility trial would hit the group harder now because expectations have reset upward and valuations are more momentum-sensitive.

Contrarian angle: the best risk/reward may not be owning the straight-line upside after the gap, but using the rally to structure asymmetric exposure. If the policy is durable, these names can re-rate for months; if it is mostly optics, implied volatility should remain elevated enough to monetize through defined-risk structures rather than chasing common stock at stretched multiples.

Key Decisions for Investors

• Add ATAI and CMPS on pullbacks over the next 3-5 sessions; preferred expression is a basket long with a 6-9 month horizon, targeting continuation if policy implementation evidence emerges.
• Buy 3-6 month call spreads in CMPS instead of outright stock to capture further multiple expansion while capping downside if the move retraces on implementation skepticism.
• Pair trade: long ATAI / short a basket of lower-quality, preclinical psychedelic names or any thinly funded private proxies if liquid; thesis is capital concentration into the most de-risked platforms over the next 1-2 quarters.
• If already long from before the headline, trim 20-30% into strength and retain a core position for the 3-9 month policy-validation window; this lowers mark-to-market risk without abandoning upside.
• Do not chase after the opening squeeze if implied vol stays elevated; wait for a consolidation day and only add if volume remains above average, which would indicate institutional rather than retail-driven follow-through.